Logo image
The Lignan (-)-Hinokinin Displays Modulatory Effects on Human Monoamine and GABA Transporter Activities
Journal article   Open access   Peer reviewed

The Lignan (-)-Hinokinin Displays Modulatory Effects on Human Monoamine and GABA Transporter Activities

Julie Marie V. Timple, Lizandra Guidi Magalhaes, Karen Cristina Souza Rezende, Ana Carolina Pereira, Wilson Roberto Cunha, Marcio Luis Andrade e Silva, Ole Valente Mortensen and Andreia C. K. Fontana
Journal of natural products (Washington, D.C.), v 76(10), pp 1889-1895
01 Oct 2013
PMID: 24112084
url
https://doi.org/10.7270/q2805413View
Open

Abstract

Chemistry, Medicinal Life Sciences & Biomedicine Pharmacology & Pharmacy Plant Sciences Science & Technology
The neurotransmitter transporters of the SLC6 family play critical roles in the regulation of neurotransmission and are the primary targets of therapeutic agents used to treat clinical disorders involving compromised neurotransmitter signaling. The dopamine and norepinephrine transporters have been implicated in clinical disorders such as attention deficit hyperactivity disorder (ADHD) and substance abuse. The GABA transporters (GATs) serve as a target for anxiolytic, antidepressant, and antiepileptic therapies. In this work, the interaction with neurotransmitter transporters was characterized for a derivative of the lignan (-)-cubebin (1), namely, (-)-hinokinin (2). Using in vitro pharmacological assays, 2 selectively inhibited the human dopamine and norepinephrine transporters, in a noncompetitive manner possibly mediated by binding to a novel site within the transporters, and displayed low affinity for the serotonin transporter. Compound 2 also specifically inhibited the GAT-1 GABA transporter subtype. Compound 2 is not a substrate of the carriers as it had no effect on the efflux of either of the neurotransmitters investigated. This compound is inactive toward glutamate and glycine transporters. These results suggest that 2 may serve as a tool to develop new therapeutic drugs for ADHD and anxiety that target the DAT, NET, and GAT-1 transporters.

Metrics

6 Record Views
24 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Chemistry, Medicinal
Pharmacology & Pharmacy
Plant Sciences
Logo image